SuperGen Releases Interim Data Clarification From Dacogen™ Phase III Clinical Study in Myelodysplastic Syndrome Following Analyst/Investigator Conference Call

SuperGen Releases Interim Data Clarification From Dacogen™ Phase III Clinical Study in Myelodysplastic Syndrome Following Analyst/Investigator Conference Call

Published Study Results Show Low-Dose Outpatient Dosing Schedule of Dacogen™ Useful in Patients With Hematological Malignancies

Published Study Results Show Low-Dose Outpatient Dosing Schedule of Dacogen™ Useful in Patients With Hematological Malignancies

Webcast Alert: SuperGen Presentation at Informed Investors Biotech/Healthcare Virtual Forum to be Webcast On Thursday, February 26, 2004, 10:30 am ET

Webcast Alert: SuperGen Presentation at Informed Investors Biotech/Healthcare Virtual Forum to be Webcast On Thursday, February 26, 2004, 10:30 am ET

SuperGen Inc. Announces Intent to Withdraw the Registration Statement for Public Offering of Shares of Common Stock

SuperGen Inc. Announces Intent to Withdraw the Registration Statement for Public Offering of Shares of Common Stock

SuperGen Announces Interim Data from Dacogen™ Phase III Clinical Study in Myelodysplastic Syndrome

SuperGen Announces Interim Data from Dacogen™ Phase III Clinical Study in Myelodysplastic Syndrome

SuperGen, Inc. Announces Filing of Registration Statement for Public Offering of Shares of Common Stock

SuperGen, Inc. Announces Filing of Registration Statement for Public Offering of Shares of Common Stock